Bcl-2 can be converted into a proapoptotic molecule by nuclear receptor Nur77. However, the development of Bcl-2 converters as anticancer therapeutics has not been explored. Here we report the identification of a Nur77-derived Bcl-2-converting peptide with 9 amino acids (NuBCP-9) and its enantiomer, which induce apoptosis of cancer cells in vitro and in animals. The apoptotic effect of NuBCPs and their activation of Bax are not inhibited but rather potentiated by Bcl-2. NuBCP-9 and its enantiomer bind to the Bcl-2 loop, which shares the characteristics of structurally adaptable regions with many cancer-associated and signaling proteins. NuBCP-9s act as molecular switches to dislodge the Bcl-2 BH4 domain, exposing its BH3 domain, which in turn blocks the activity of antiapoptotic Bcl-X L .
INTRODUCTION
Members of the Bcl-2 family are critical regulators of apoptosis, an important biological process that eliminates cells with increased malignant potential such as those with damaged DNA or aberrant cell cycling (Cory et al., 2003; Green and Kroemer, 2004; Reed, 1998; Vander Heiden and Thompson, 1999) . They possess at least one of four conserved motifs called Bcl-2 homology (BH) domains. The family is divided into three subclasses based on the number of BH domains and their function: the antiapoptotics, including Bcl-2 and Bcl-X L , which possess sequence conservation through BH1-4; the multidomain proapoptotics, such as Bax and Bak, which possess BH1-3; and the BH3-only proapoptotic molecules such as Bid, Bim, and Bad (Cory et al., 2003; Green and Kroemer, 2004; Reed, 1998; Vander Heiden and Thompson, 1999) . The Bcl-2 family regulates apoptosis through interactions between its proapoptotic and antiapoptotic family members. BH3-only proteins convey diverse death signals by directly or indirectly activating Bax and/or Bak, which can induce permeabilization of the outer mitochondrial membrane and release apoptogenic factors needed to activate the caspases Leber et al., 2007; Letai et al., 2002; Willis and Adams, 2005; Willis et al., 2007) . Antiapoptotic family members inhibit death by restraining Bax and Bak activity and/or sequestering BH3-only members. Approaches targeting prosurvival Bcl-2 family members, such as BH3 domain-derived peptides or chemical inhibitors such as ABT-737 (Bouillet and Strasser, 2002; Degterev et al., 2001; Oltersdorf et al., 2005; Reed, 2002; Walensky et al., 2004) , are being developed, which show significant anticancer activities. These BH3 peptides and chemical inhibitors act by binding to the hydrophobic groove formed by the BH1-3 domains of the prosurvival proteins and antagonizing their survival function, resulting in release of proapoptotic members that activate apoptosis.
The functional phenotype of some Bcl-2 family members such as Bcl-2 can be reversed in some cellular contexts. For example, mutants of the Bcl-2-homolog Ced-9 appear to promote rather than prevent apoptosis in C. elegans (Xue and Horvitz, 1997) .
SIGNIFICANCE
We report that a Nur77-based peptide and its enantiomer bind to the Bcl-2 loop, converting Bcl-2 from a protector to a killer of cancer cells. Our results provide mechanistic insight into Bcl-2 conversion and identify a new direction for Bcl-2-based drug leads and cancer drug development. These findings should appeal to a broad audience of clinicians, cancer biologists, molecular biologists, and drug designers who have followed therapeutic approaches targeting Bcl-2 and the underlying molecular mechanisms. In addition, peptide and protein chemists and structural biologists will be intrigued by the activity of the NuBCP-9 enantiomer, which has important mechanistic implications with broad potential for cancer therapeutics.
Likewise, Bcl-2 homologs in Drosophila can manifest either cytoprotective or cytodestructive phenotypes, depending on cellular context (Colussi et al., 2000; Igaki et al., 2000) . The mechanisms responsible for the phenotypic conversion of Bcl-2 are largely undefined. However, the unstructured loop of Bcl-2, which links the BH3 and BH4 domains, appears important (Moll et al., 2006; Zhang, 2007) . When the Bcl-2 loop is cleaved by caspase-3, Bcl-2 is converted to a proapoptotic protein similar to Bax (Cheng et al., 1997; Grandgirard et al., 1998) . Phosphorylation of the loop has also been speculated to convert Bcl-2 to a proapoptotic form (Blagosklonny, 2001) . It inhibits binding of Bcl-2 to multidomain and BH3-only proapoptotic family members (Bassik et al., 2004) and the autophagic protein beclin 1 (Wei et al., 2008) . We recently reported that nuclear receptor Nur77 converts Bcl-2 into a killer by binding its loop . Nur77 (also called TR3 or NGFI-B) is a potent proapoptotic member of the nuclear receptor superfamily (Moll et al., 2006; Zhang, 2007) . It often translocates from the nucleus to mitochondria in response to different death signals, where it binds Bcl-2, inducing a conformational change (Li et al., 2000; . Nur77 translocation to mitochondria and its induction of a Bcl-2 conformational change have also been implicated in the negative selection of thymocytes in vitro and in animals (Thompson and Winoto, 2008) , indicating a physiological role for the Nur77-Bcl-2 interaction. Interestingly, p53 also binds the Bcl-2 loop (Moll et al., 2006) , which then acts like a BH3-only protein to activate Bax or Bak by releasing BH3-only proteins such as Bid Leu et al., 2004; Mihara et al., 2003) .
The apoptotic effect of Nur77 appears to be clinically relevant, as the expression of the Nur77 subfamily member Nor-1 is positively correlated with survival of diffuse large B cell lymphoma patients (Shipp et al., 2002) and Nur77 downregulation is associated with metastasis of several primary solid tumors (Ramaswamy et al., 2003) . Thus, targeting the Nur77-Bcl-2 apoptotic pathway is an attractive approach for developing cancer therapeutics. The ability of Nur77 to convert Bcl-2 distinguishes this death protein from proapoptotic Bcl-2 family proteins, whose activities are restrained by prosurvival Bcl-2 family members. It also offers an opportunity to design drugs that are likely to be effective against cancer cells with high Bcl-2 levels. Here, we report the identification of a short Nur77-derived peptide and its enantiomer that act as molecular switches to induce a Bcl-2 conformational change, converting it from a protector to a killer of cancer cells in vitro and in animals.
RESULTS
A 9 Amino Acid Peptide from Nur77 Induces Apoptosis To develop Bcl-2 converters that induce apoptosis in cancer cells with high Bcl-2 levels, peptides corresponding to subregions of a Nur77 fragment known to interact with Bcl-2 were synthesized and conjugated with the cell-penetrating peptide (CPP) D-Arg octamer (r8) (Jones et al., 2005) ( Figure 1A ). Among these, a 20 amino acid peptide (aa 480-499) (NuBCP-20) exhibited potent apoptotic effect in various cancer cell lines, being more potent than a BH3 peptide derived from the proapoptotic Bcl-2 family member Bid (Letai et al., 2002 ) (see Figures S1 and S2 available online). Serial deletion identified a 9 aa Nur77 peptide, NuBCP-9, which effectively induced apoptosis of breast cancer cells ( Figure 1B ; Figure S2 ). Neither NuBCP-20 nor NuBCP-9 induced apoptosis of normal primary mammary epithelial cells ( Figure 1B ; Figure S1 ). NuBCP-9 is considerably shorter than the shortest BH3 peptide that binds Bcl-2. Further deletion from either its N-terminal or Cterminal end or substituting Ala for the NuBCP-9 terminal amino acids (NuBCP-9/AA) completely abolished its apoptotic effect ( Figure S2 ). NuBCP-9 linked to other CPPs, penetratin, or transportan 10 (Jones et al., 2005) as well as r8 by a disulfide bond exhibited a similar degree of apoptosis ( Figure S2 ). Since disulfide bonds are rapidly reduced in cells, the apoptotic effect of NuBCP-9 is not due to its linkage with CPPs.
While investigating the sequence requirements for NuBCP-9, we discovered that replacing L-amino acids with D-amino acids did not diminish its apoptotic effect. Peptide enantiomers have been reported to interact with several proteins , including calmodulin, a3b1 integrin, DnaJ (Hsp40) cochaperone, and CXCR4, which like Bcl-2 are characterized by large natively disordered loops. In contrast, the enantiomer of Bad BH3 peptide was not apoptotic ( Figure 1C ), demonstrating different modes of action of the NuBCP-9 and Bad BH3 peptides.
Induction of Apoptosis by NuBCP-9 Is Bcl-2 Dependent
We next examined whether NuBCP-9-induced apoptosis is dependent on Bcl-2 expression. NuBCP-9 and its enantiomer showed little effect on Jurkat cells (<20% apoptosis). However, both peptides induced extensive apoptosis (>50%) in Jurkat cells stably expressing Bcl-2 ( Figure 1D ). In contrast, apoptosis induced by staurosporine (STS) and Bid BH3 peptide was attenuated by Bcl-2 overexpression in Jurkat cells ( Figure S3 ), demonstrating the dual role of Bcl-2. Stable expression of Bcl-2 in CEM leukemia cells also potentiated the apoptotic effect of Nur77 peptide but prevented the killing by STS and Bad BH3 peptide ( Figure S4 ). The apoptotic effect of NuBCP-9 was further evaluated in mouse embryonic fibroblasts (MEFs) and Bcl-2 knockout MEFs (Bcl-2 À/À MEFs). Although the apoptotic effect of STS and Bad BH3 peptide was enhanced in Bcl-2 À/À MEFs ( Figure 1E ), NuBCP-9 and D-NuBCP-9 induced apoptosis of wild-type MEFs but not Bcl-2 À/À MEFs in a dose-dependent ( Figure 1F ) and time-dependent ( Figure 1G ) manner. Furthermore, suppression of Bcl-2 expression by siRNA or antisense oligonucleotides reduced the killing effect of NuBCP-9 enantiomers ( Figures S5 and S6 ). Thus, Bcl-2 is a major target of NuBCP-9s. NuBCP-induced apoptosis requires Bax or Bak, as the peptides induced apoptosis similarly in wild-type, Bax 
Bak
À/À MEFs ( Figure 2C ). To further evaluate NuBCPs,
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Nur77-Derived Peptide Converts Bcl-2 into a Killer their effects on the growth of tumors formed in severe combined immunodeficiency (SCID) mice were examined. Injection of L-or D-NuBCP-9, but not control peptide (NuBCP-9/AA), dramatically suppressed the growth of MDA-MB435 cancer cell xenografts in mice ( Figure 2D ; Figure S2C ) and potently induced apoptosis of tumor cells as revealed by TUNEL staining ( Figures 2E and 2F) . Furthermore, D-NuBCP-9 induced regression of tumors (Figure 2G) . Thus, NuBCP-9 and its enantiomer effectively induce apoptosis in vitro and in animals, demonstrating their therapeutic potential.
NuBCP-9 and Its Enantiomer Bind Bcl-2 To determine whether NuBCPs bind Bcl-2, cDNAs encoding the residues 478-504 (Nur77/478-504) and 489-497 (Nur77/ 489-497, equivalent to NuBCP-9) of Nur77 were fused with green fluorescent protein (GFP) cDNA. When transfected into HEK293T cells, GFP-fused Nur77 fragments were precipitated by anti-Bcl-2 antibody only when Bcl-2 was coexpressed ( Figure 3A ). The coprecipitation was inhibited by addition of NuBCP-9, but not Smac peptide (data not shown). To study whether D-NuBCP-9 interacts with Bcl-2, we used Cells (10,000 per well) were seeded in medium containing 5% FBS and then exposed to the indicated concentration of NuBCP-9 peptides conjugated with penetratin peptide (NuBCP-9-pen) ( Figure S2) a competition assay. Nur77 lacking its DNA-binding domain (DBD), Nur77/DDBD, bound Bcl-2 , and binding was inhibited by NuBCP-9 or D-NuBCP-9 ( Figure 3B ). GFP-Nur77/478-504 also bound to the antiapoptotic Bcl-2 family members Bcl-B and Bfl-1, but not Bcl-X L or Mcl-1 ( Figure 3C ). Like Nur77 protein , the killing effect of NuBCP-9 was enhanced by overexpression of Bcl-B in HeLa cells and inhibited by suppression of Bcl-B expression by siRNA in H460 cells ( Figure S6 ). These results suggest that NuBCP-9 also converts Bcl-B into a proapoptotic molecule. We next used fluorescence polarization (FP) assays to determine whether NuBCP-9s bind Bcl-2. GST-Bcl-2, but neither GST-Bcl-X L nor GST, induced a concentration-dependent FP of FITC-NuBCP-9 and FITC-D-NuBCP-9, while the FP of FITCNuBCP-9/AA was little affected ( Figure 3D ). In addition, unconjugated NuBCP-9 and D-NuBCP-9 competed with binding of FITC-L-NuBCP-9 or FITC-D-NuBCP-9 to GST-Bcl-2, whereas NuBCP-9/AA did not ( Figure 3E ). Thus, NuBCP-9 and DNuBCP-9 bind Bcl-2 directly and competitively. The Bcl-2 domain targeted by NuBCPs is distinct from that targeted by BH3 peptides, as shown by the failure of either a BH3 peptide (Bak BH3) or a potent small-molecule inhibitor (ABT-737) that targets the Bcl-2 BH3-binding site to reduce FITC-NuBCP-9 binding to GST-Bcl-2 ( Figure 3E ).
The GFP-Nur77/489-497 and GFP-Nur77/478-504 fusions colocalized extensively with RFP-Mito, a red fluorescent protein (RFP) fused to a mitochondria-targeting sequence ( Figure 3F ). FITC-D-NuBCP-9-r8 also displayed significant colocalization with RFP-Mito. Thus, NuBCP-9 and its enantiomer, like Nur77, bind Bcl-2 and target mitochondria.
NuBCP-9s Induce Bcl-2 Conformational Change
Conversion of Bcl-2 involves a conformational change that exposes its BH3 domain . BH3 domain exposure is detectable with an antibody against Bcl-2 BH3 peptide ( Figure S7 ). The effect of NuBCPs on Bcl-2 conformation was examined by immunoprecipitation assays ( Figure 4A ).
The Bcl-2 BH3 domain antibody precipitated endogenous Bcl-2 in cells treated with NuBCP-9 or D-NuBCP-9, but not NuBCP-9/AA, showing that NuBCP-9s induce a Bcl-2 conformational change. In contrast, tBid BH3 and Bad BH3 peptides did not induce this effect, despite their induction of apoptosis. This was confirmed by flow cytometry analysis, which showed a strong enhancement in fluorescence upon staining with BH3 antibody of cells exposed to NuBCP-9s, but not NuBCP-9/AA, tBid BH3, or Smac peptide ( Figure 4B ). NuBCP-9-induced Bcl-2 BH3 domain immunofluorescence was observed in the presence of the caspase inhibitor zVAD, excluding the involvement of caspases in the Bcl-2 conformational change ( Figure S7D ). The NuBCP-induced Bcl-2 conformational change was also observed in solid tumors ( Figure 2F ). The overlapping of TUNEL staining with Bcl-2 BH3 immunofluorescence in tumors treated with NuBCP-9 ( Figure 2F ) is consistent (A) HEK293T cells transfected with GFP-Nur77/489-497 or GFP-Nur77/478-504 (2 mg) together with or without Bcl-2 expression plasmid (0.8 mg) were analyzed by coimmunoprecipitation (CoIP) using anti-Bcl-2 antibody, followed by western blotting (WB) using either anti-GFP or anti-Bcl-2 antibody . Cells were transfected in six-well plates at 80% confluency. (B) HEK293T cells transfected with GFP-Nur77/DDBD and Bcl-2 were exposed to NuBCP-9 or D-NuBCP-9, and interaction was analyzed by CoIP. (C) Interaction of NuBCP with antiapoptotic Bcl-2 family members, Bcl-B, Bfl-1, and Bcl-2. HEK293T cells in six-well plates transfected with GFP-Nur77/478-504 (2 mg) together with or without the indicated Myc-tagged Bcl-2 family member expression plasmids (0.8 mg) were analyzed by CoIP, followed by WB. with the notion that NuBCP-9-induced Bcl-2-dependent apoptosis is correlated with exposure of the Bcl-2 BH3 domain. We next determined whether NuBCPs can induce a conformational change of purified GSTBcl-2 protein using circular dichroism (CD) analysis. Our results showed similar changes in GST-Bcl-2 protein spectra when it was incubated with NuBCP-9 or D-NuBCP-9, but not NuBCP-9/AA ( Figure 4C ; Figure S8 ). The fact that NuBCP-9 and D-NuBCP-9 display mirror image spectra (Figures S8-S10) while inducing identical changes in the Bcl-2 spectra ( Figure 4C ; Figure S8 ) indicates that NuBCP-9 and D-NuBCP-9 do not contribute significantly to the spectral changes. Binding is saturable and stoichiometric with a K d of 2.1 ± 0.2 mM for NuBCP-9 and 2.0 ± 0.1 mM for D-NuBCP-9 ( Figures 4D and 4E ), in agreement with FP assays ( Figure 3E ). In contrast, NuBCP-9, D-NuBCP-9, and NuBCP-9/AA had no effect on CD spectra for GST or GST-Bcl-X L ( Figures S9 and S10) . Thus, the NuBCP-induced Bcl-2 conformational change observed in cells can be accounted for by direct binding of NuBCPs to Bcl-2 in a specific 1:1 complex.
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NuBCP-9s Are Capable of Binding to the Loop of Bcl-2 The observation that NuBCP-9 and its enantiomer exhibit similar if not identical effects on Bcl-2 function raised the possibility that their binding interface or interfaces are structurally adaptive. The large regulatory loop of Bcl-2 is predicted to be natively unstructured ( Figure S11 ) and like other loops of this class may be structurally adaptive (Dyson and Wright, 2005; Iakoucheva et al., 2002) . Cell-based coimmunoprecipitation (CoIP) ( Figure 5A ) showed that a Bcl-2 N-terminal fragment containing the BH4 domain and loop, Bcl-2/1-90, interacted with Nur77 mutants (Nur77/DC3, Nur77/DC1, and Nur77/478-504) known to bind Bcl-2. In vitro, NuBCP-9 and its enantiomer bound similarly and competitively to GST-Bcl-2/1-90 as revealed by FP assays ( Figure 5B ). CD analysis showed that both NuBCP-9s induced similar changes in GST-Bcl-2/1-90 spectra ( Figure 5C ; Figure S12 ). The binding affinities of NuBCP-9s for Bcl-2/1-90 Figure 5B ) are similar to the affinities for Bcl-2 ( Figure 4E ), as are the stoichiometries (Figures 4D and 4E ; Figure 5D ). Thus, Bcl-2/1-90 retains the ability of Bcl-2 to bind to NuBCP-9s, excluding the involvement of the hydrophobic groove in Bcl-2, consistent with the inability of a BH3 peptide and ABT-737 to compete with the binding of NuBCP-9 to Bcl-2 ( Figure 3E ). We next examined whether the Bcl-2 loop alone is capable of binding to NuBCP-9s. The Myc-tagged Bcl-2 loop, Myc-Bcl-2/29-90, interacted with GFP-Nur77/DC3 ( Figure 5E ). The interaction was inhibited by NuBCP-9 or D-NuBCP-9, but not by NuBCP-9/AA ( Figure 5F ). Mutations of Thr69 and Ser70 in the loop slightly enhanced its interaction with Nur77/ DC3, while insertion of 10 aa in the loop largely impaired the interaction ( Figure 5G ). Strong support was provided by FP assays showing that both peptides bound to GST-Bcl-2/29-90 protein ( Figure 5H) . Also, NuBCP-9 and its enantiomer, but not the mutant peptide, competed with FITC-NuBCP-9 for binding to Figure 3D and Figures 5B and 5H using Prism software. EC 50 values for unlabeled NuBCP-9s binding the same Bcl-2 constructs were derived from single-site FP assay competition curves shown in Figure 3E and Figures 5B and 5H Figure 4D ; Figure 5D ) using nonlinear regression analysis for a one-site binding model. Stoichiometry ± SD was determined as described previously (Jones et al., 2002) .
GST-Bcl-2/29-90. Furthermore, CD analysis showed a similar change of the spectra of GST-Bcl-2/29-90 protein by NuBCP-9 and its enantiomer ( Figure 5I ; Figure S13 ). Bcl-2 and Bcl-2/ 1-90 underwent greater NuBCP-induced changes in their CD spectra than Bcl-2/29-90, suggesting involvement of the BH4 domain. Thus, NuBCP-9 and its enantiomer bind to the Bcl-2 loop.
NuBCP-9 Induces Bcl-2-Dependent Bax Activation Our observation that NuBCP-9-induced apoptosis is dependent on Bax and/or Bak prompted us to investigate whether and how NuBCP-9 activates Bax. In vitro assays using isolated mitochondria showed that both NuBCP-9 and D-NuBCP-9 induced Bax dimerization, trimerization, and especially oligomerization ( Figure 6A ) in a concentration-dependent manner ( Figure 6B ). Such an effect occurred only in the presence of GSTBcl-2 protein. In DoHH2 lymphoma cells that express high levels of Bcl-2 (Dyer et al., 1996) , NuBCP-9s induced Bax dimerization/ oligomerization ( Figure 6C ). Transfection of Bcl-2/1-95 inhibited both NuBCP-9-induced apoptosis ( Figure 6D ) and Bax activation ( Figure 6E ). NuBCP-9 also induced Bax activation in H460 cells as revealed by flow cytometric analysis of Bax immunostaining with an anti-Bax antibody (6A7) that recognizes active Bax conformation (Nechushtan et al., 1999 ) ( Figure 6F ). Similar to the effect in DoHH2 cells, Bcl-2/1-90 potently inhibited NuBCP-9-induced apoptosis ( Figure 6G ) and Bax activation in H460 cells ( Figure 6H ). Furthermore, expression of Bcl-2/DBH3, a Bcl-2 mutant lacking its BH3 domain, inhibited NuBCP-9-induced apoptosis ( Figure 6G ) and Bax activation ( Figure 6H ). NuBCP-9-induced Bax activation was observed in wild-type MEFs but not Bcl-2 knockout MEFs ( Figure 6I ). However, transfection of Bcl-2 into Bcl-2 À/À MEFs restored the ability of NuBCP to activate Bax ( Figure 6J) . Together, these cell-free and cell-based studies demonstrate that NuBCP-9 induces Bax activation in a Bcl-2-dependent manner and that the loop and BH3 regions of Bcl-2 are crucial.
NuBCP-9s Disrupt Bcl-2 Intramolecular Interaction
To study the mechanism by which enantiomeric NuBCPs induce Bcl-2 conformational change, we first examined how the antiapoptotic Bcl-2 conformation was maintained and found that the Bcl-2 BH4 domain could act like a brace to stabilize the C-terminal antiapoptotic BH3-binding pocket. CoIP revealed that a Bcl-2 N-terminal sequence containing the BH4 domain bound a Bcl-2 mutant from which the BH4 domain was removed (Bcl-2/DBH4) ( Figure 7A ), suggesting an intramolecular interaction between the BH4 domain and the C-terminal region. The BH4 domain could not bind full-length Bcl-2, likely due to inaccessibility of a BH4-binding site in the C-terminal region. However, a strong interaction was observed when Nur77/DDBD or Nur77/DC3 was coexpressed ( Figure 7B ), suggesting that binding of Nur77 mutants with Bcl-2 reorganizes Bcl-2, leading to the exposure of the BH4-binding site in the C-terminal region. Similarly, addition of NuBCP-9 and its enantiomer induced the binding of the BH4 domain to Bcl-2 ( Figure 7C) . Removal of the BH4 domain through caspase cleavage of the Bcl-2 loop converts it into a apoptotic molecule (Cheng et al., 1997; Grandgirard et al., 1998) . Consistently, a Bcl-2 mutant lacking its BH4 domain was extensively immunostained by anti-Bcl-2 BH3 domain antibody, while the wild-type Bcl-2 protein was not, indicating that the exposure of the BH3 epitope is blocked directly or indirectly by the BH4 domain ( Figure 7D ). Thus, our data unravel a mechanism of Bcl-2 conversion in which binding of NuBCP-9 or its enantiomer to the Bcl-2 loop dislodges its BH4 domain, leading to a proapoptotic conformation that exposes the BH3 domain.
NuBCP-9 Disrupts Bcl-2 Interaction with tBid in Liposomes
We next determined how NuBCP-9-induced changes in Bcl-2 conformation result in Bax activation and apoptosis. One way in which Bcl-2 prevents death is by sequestering activator BH3-only family members (such as Bid) and preventing their interaction with Bax/Bak (Cheng et al., 2001; Kuwana et al., 2005; Letai et al., 2002) . We recently showed that the interaction between membrane-bound Bcl-2 and tBid results in a conformational alteration in Bcl-2 that induces permeabilization of liposomal membranes to the 0.5 kDa fluorescent dye cascade blue (CB) . Unlike the interaction of tBid with Bax, the pores in liposomal membranes that result from the interaction of tBid with Bcl-2 are relatively small, allowing the release of CB but not CB-labeled 10 kDa dextran. Although the physiological significance of the tBid-induced Bcl-2 membrane-permeabilizing activity is largely elusive, it offered an opportunity to study the effect of NuBCP-9 on tBid/Bcl-2 interaction in liposomes. When NuBCP-9 was added with Bcl-2 and tBid to liposomes, NuBCP-9, but not NuBCP-9/AA, inhibited the membrane permeabilization induced by tBid/Bcl-2 interaction in a dose-dependent manner ( Figure 7E ). NuBCP-9 at 1 mM was sufficient for inhibition, which could not be further increased by using 10 mM peptide. This result suggests that 10 mM is a saturating peptide concentration, consistent with our binding studies ( Figure 4E ). NuBCP-9 alone had no effect on the membrane permeability, even at the highest dose (10 mM). Thus, NuBCP-9 can inhibit the interaction of Bcl-2 with an activator BH3-only protein, which in turn may activate Bax.
NuBCP-9 Does Not Convert Bcl-2 to a Direct Activator of Bax Some BH3-only proteins, including Bid and Bim (termed activators), induce Bax/Bak oligomerization through their direct interaction with Bax/Bak (Cheng et al., 2001; Kuwana et al., 2005; Letai et al., 2002) . We next tested whether the NuBCP-9-converted Bcl-2 could also function as a direct activator of Bax. As shown in Figure 7F , while adding NuBCP-9 even at a saturating concentration of 10 mM to 50 nM Bcl-2 induced a marginal but reproducible membrane permeabilization of liposomes, further addition of 50 nM Bax failed to increase the membrane permeability. In contrast, 5 nM tBid strongly induced membrane permeabilization by 50 nM Bax, releasing a cytochrome c surrogate, 10 kDa CB-dextran ( Figure 8E ). Thus, NuBCP-9 does not induce Bcl-2 to directly activate Bax.
BH3 Peptide from Bcl-2 Reverses Bcl-X L 's Inhibition of tBid-Activated Bax in Liposomes
To study whether NuBCP-9-induced exposure of the BH3 domain in Bcl-2 acts indirectly to induce apoptosis by competing with Bax or Bak for the BH3-binding pockets of antiapoptotic Bcl-2 family members, we mutated two highly conserved BH3 residues (Leu97 and Asp102) in Bcl-2 ( Figure 8A ) that correspond with residues in the Bak BH3 peptide that are required for displacing BH3 proteins and peptides from the BH3-binding pockets of antiapoptotic Bcl-2 family members (Sattler et al., 1997) . The Bcl-2 double mutant (Bcl-2/L97A/D102A) acted dominant negatively, suppressing Nur77 peptide-induced apoptosis ( Figure 8B ). We then tested whether the Bcl-2 BH3 peptide could directly inhibit Bcl-X L blocking of tBid-induced Bax permeabilization of liposomes encapsulating the large 10 kDa CB-dextran. As shown in Figure 8C , the inhibitory effect of Bcl-X L was reversed by Bcl-2 BH3 in a dose-dependent manner, while the mutant BH3 peptide had no effect. Also, the Bcl-2 BH3 peptide alone did not induce Bax-dependent membrane permeabilization, consistent with the observation that the addition of NuBCP-9 to Bcl-2 did not induce Bax-dependent membrane permeability ( Figure 7F ). Next, we showed using the FP assay that F5M-Cys-labeled Bcl-2 BH3 peptide, but not the doublemutant peptide, bound to GST-Bcl-X L protein (K d = 144.6 ± 11 nM) ( Figure 8D ). Binding of the Bcl-2 BH3 peptide to Bcl-X L confirmed a previous report (Sattler et al., 1997) .
We next determined whether Bcl-2 in the presence of NuBCP-9 could mimic the inhibitory effect of the Bcl-2 BH3 peptide on the activity of Bcl-X L against tBid-activated Bax. A saturating concentration of NuBCP-9 (10 mM) was preincubated with Bcl-2 protein to insure full conversion before adding Bcl-X L . Figure 8E shows that Bcl-X L inhibition of tBid-induced Bax permeabilization was reversed by NuBCP-9 in a Bcl-2-dependent manner. In contrast, the addition of Bcl-2 to Bcl-X L further inhibited the tBid-induced Bax activity. Figure 8E also shows that, similar to Bcl-X L , Bcl-2 alone inhibited the tBid/Bax-mediated membrane permeabilization. Unlike the Bcl-X L case, the Bcl-2 inhibition was reversed by the addition of NuBCP-9. Together, our liposome results demonstrate that NuBCP-9-induced Bcl-2 conformational change not only neutralizes Bcl-2's inhibition of Bax-mediated membrane permeabilization but also exposes the Bcl-2 BH3 motif, neutralizing Bcl-X L 's inhibition of Bax ( Figure 8F ).
DISCUSSION
Here we report the identification and characterization of a 9 aa Nur77 Bcl-2-converting peptide, NuBCP-9, which potently induces apoptosis through a pathway that is potentiated by Bcl-2 expression in vitro and in animals ( Figure 1; Figure 2 ; Figures S3 and S4 ). Bcl-2 is an attractive drug target because its levels are elevated in a majority of human cancers and correlate with the resistance of cancer cells to many chemotherapeutic drugs and g irradiation. From a therapeutic viewpoint, Bcl-2 overexpression may be advantageous because it distinguishes many cancer cells from normal cells. In this regard, several strategies taking advantage of this difference are currently being investigated, which may lead to improved cancer treatments. Currently, targeting Bcl-2 has mostly relied on antisense oligonucleotides that inhibit Bcl-2 expression or BH3 peptides and small-molecule surrogates that bind the Bcl-2 BH3-binding pocket, antagonizing its antiapoptotic activity (Bouillet and Strasser, 2002; Degterev et al., 2001; Oltersdorf et al., 2005; Reed, 2002; Walensky et al., 2004) . Although it has been known for some time that Bcl-2 can be converted to a proapoptotic form by caspase-3 (Cheng et al., 1997; Grandgirard et al., 1998) or activating proteins including Nur77 , it has been unclear whether this conversion provides a basis for cancer drug development. NuBCP-9 acts by inducing a Bcl-2 conformational change, raising prospects that NuBCP-9-based drugs and small-molecule Bcl-2 converters might be developed for treating cancers with elevated levels of Bcl-2. The NuBCP-9 enantiomer is protease resistant , an important consideration for peptide-based drug development, while short peptides are sometimes forerunners for small-molecule drug development. Our observation that NuBCP-9 and its enantiomer effectively induce tumor regression in animals establishes them as potential therapeutic leads for the treatment of Bcl-2-overexpressing cancers.
Our data demonstrate that NuBCP-9 induces a Bcl-2 conformational change by binding the Bcl-2 loop to dislodge its BH4 domain ( Figures 7A-7C) , which exposes the BH3 domain (Figure 4 ; Figure 7D ; Figure S7 ). These results provide further support for the Bcl-2 loop as a regulator of its activity. The Bcl-2 loop is predicted to be natively unstructured ( Figure S11 ). Recent studies have shown that a large unstructured loop can bind different proteins by structural adaptation through coupled folding (Dyson and Wright, 2005) . The majority of human cancer-associated and signaling proteins are predicted to have large, natively unstructured loops, which may account for their positions at the center of many biological processes (Dyson and Wright, 2005; Li, 2005; Iakoucheva et al., 2002) . The observation that both NuBCP-9 and its enantiomer bind the Bcl-2 loop may be a manifestation of an unstructured, conformationally adaptable loop. The Bcl-2 family of proteins is central to apoptosis. Thus, it is not surprising that the Bcl-2 loop shares many of the characteristics of structurally adaptable regulatory loops, including its large size (69 residues), high proline content (22%), several phosphorylation and caspase cleavage sites, and at least five different protein binding partners Deng et al., 2006; Kang et al., 2005; Ueno et al., 2000) . Consequently, it might be expected that Bcl-2 conversion is subject to multiple levels of regulation, depending on cell type and cellular environment. Of particular interest is that the Bcl-2 loop is enriched by proline residues, which are widely distributed in disordered regulatory loops of proteins from prokaryotes to eukaryotes and display promiscuity and versatility in proteinprotein interactions (Li, 2005) . Structural analysis of the Bcl-2/NuBCP complex will eventually resolve whether these proline-rich sequences are responsible for binding to NuBCP-9 and its enantiomer. As many human cancer-associated and signaling proteins contain large, natively disordered regulatory loops (Dyson and Wright, 2005; Iakoucheva et al., 2002; Li, 2005) , proteolytically stable D-peptides may provide a rich source for new drug leads. Induction of apoptosis by NuBCP-9 required expression of either Bax or Bak ( Figure 1H ) and was associated with their activation ( Figure 6 ). However, the addition of NuBCP-9 to Bcl-2, unlike tBid, did not induce Bax-dependent permeabilization of mitochondrial outer membrane liposomes ( Figure 7F ), arguing against a direct activation mechanism. Consistent with an indirect activation mechanism, we found that NuBCP-9 inhibited Bcl-2 interaction with tBid ( Figure 7E ), suggesting that NuBCP-9 may indirectly induce Bax activation by inhibiting Bcl-2 interaction with activator BH3-only proteins. Investigating this further, our liposome data showed that inhibition of tBid-activated Bax by Bcl-2 or Bcl-X L was reversed by NuBCP-9 ( Figure 8E ). Our results are reminiscent of previous studies showing that phosphorylation of the unstructured loop prevents Bcl-2 from binding to multidomain proapoptotic members (Bassik et al., 2004) and beclin 1, a BH3-containing autophagic protein (Wei et al., 2008) . Thus, NuBCP-9, similar to BH3 peptides or their smallmolecule surrogates, can prevent Bcl-2 from binding and sequestering proapoptotic Bcl-2 family members.
One unique property of NuBCP-9 distinguishing it from Bcl-2 inhibitors is that NuBCP-9 not only antagonizes the survival function of Bcl-2 but also induces a Bcl-2 conformation that inhibits the survival function of its antiapoptotic relatives, such as Bcl-X L (Figures 8C-8E ). Such an effect is likely mediated by its ability to induce exposure of the BH3 domain of Bcl-2 (Figures 4A and 4B; Figure 7D ; Figure S7 ). Mutagenesis of the Bcl-2 BH3 domain demonstrated that it is required for NuBCP-9-induced Bcl-2-dependent apoptosis. Thus, Bcl-2 BH3 mutants act dominant negatively to inhibit NuBCP-9-induced Bcl-2-dependent apoptosis ( Figure 6G ; Figure 8B ) and Bax activation ( Figure 6H ). Consistently, a peptide corresponding to the BH3 domain of Bcl-2 effectively neutralized the anti-Bax effect of Bcl-X L in (E) NuBCP-9 inhibits tBid/Bcl-2 interaction in liposomes. The membrane permeabilization induced by tBid/Bcl-2 interaction was monitored by the release of 0.5 kDa cascade blue (CB) dye from the liposomes after 3 hr incubation at 37 C. The release resulted in the quenching of CB fluorescence by the anti-CB antibody located outside of the liposomes. The extent of the release was determined by the value of DF Protein /DF Triton as described in Supplemental Data. The effect of NuBCP-9 or NuBCP-9/AA peptide on the release was determined by adding the corresponding peptide at the indicated concentrations to the incubation. Data shown are means of two to four independent experiments, with SD indicated by error bars.
(F) NuBCP-9-induced Bcl-2 conversion does not activate Bax in liposomes. The extent of the 0.5 kDa CB dye release by Bax and/or Bcl-2 in the absence or presence of NuBCP-9 peptide was monitored as above. Data shown are means of two to five independent experiments, with SD indicated by error bars.
liposome assays ( Figure 8C ). Similar to the Bcl-2 BH3 peptide, NuBCP-9-induced exposure of the Bcl-2 BH3 domain also neutralized the inhibitory effect of Bcl-X L on Bax activation (Figure 8E) . Thus, NuBCP-9 is distinguished from Bcl-2 inhibitors in that it also converts Bcl-2 into a ''BH3-like'' molecule that in turn inhibits its antiapoptotic relative Bcl-X L .
EXPERIMENTAL PROCEDURES
Peptide Synthesis Peptides were synthesized as described in Supplemental Experimental Procedures.
Fluorescence Polarization Assays GST-Bcl-2, GST-Bcl-X L , or GST protein was incubated briefly with FITC-or F5M-conjugated peptide with or without competitors in Greiner Fluotrac 600 96-well microplates. Fluorescence polarization was recorded using an Analyst HT 96-384 microplate reader (Molecular Devices) with excitation wavelength set at 485 nm and dynamic polarizer for emission at 530 nm.
Circular Dichroism Spectroscopy CD spectra were determined as described in Supplemental Experimental Procedures.
Apoptosis Assays
Nuclear morphological change analysis and flow cytometric analysis of annexin V binding were performed as described previously (Li et al., 2000; . For determination of DNA fragmentation in tumor tissue, TUNEL assay was used. Peptide treatments were performed in medium with 10% FBS unless otherwise specified.
Immunoblotting and CoIP Assays
For CoIP assay, HEK293T cells transfected with various expression vectors were incubated with the appropriate antibodies, and immunoprecipitates were analyzed by immunoblotting as described previously (Li et al., 2000; . For all cell-based experiments, peptides fused with a cell-penetrating-peptide (r8) were used unless otherwise stated.
Mitochondria Purification
Mitochondria were prepared from HeLa cells as described previously .
Bax Activation Assays
Cell-based and in vitro Bax activation assays were performed as described in Supplemental Experimental Procedures.
Liposome Assays
Liposomes of mitochondrial outer membrane lipid composition with cascade blue (CB) or CB-labeled 10 kDa encapsulated dextran were prepared by the and/or NuBCP-9 (10 mM) on the tBid (5 nM)/Bax (50 nM)-mediated release of 10 kDa CB-dextran from the liposomes was determined as described in Supplemental Data. Data shown are means of three to five independent experiments, with SD indicated by error bars.
(F) Model of Bcl-2 conversion by NuBCP. Binding of NuBCP to the Bcl-2 loop displaces the BH4 domain, resulting in exposure of the BH3 domain, which leads to either release of proapoptotic BH3-only members (e.g., tBid) from Bcl-2 or inhibition of other antiapoptotic relatives of the Bcl-2 family (e.g., Bcl-X L ) that leads to activation of proapoptotic multi-BH-domain proteins (e.g., Bax).
extrusion method and used for assaying Bcl-2 interactions with tBid, Bax, Bcl-X L , and NuBCP-9 as described in Supplemental Experimental Procedures.
Clonogenic Survival Assays
Clonogenic survival assays were performed as described in Supplemental Experimental Procedures.
Animal Studies
Female SCID mice (6 weeks old, Taconic) were injected with 10 6 MDA-MB435 cells. Tumors were palpable on day 7. On days 10 and 13, peptides (620 mg in 50 ml PBS) were injected into the tumor areas of five mice. Tumor volumes (length 2 3 width/2) were determined using calipers. No weight changes were observed. Established tumors in mice were injected with peptides, and tumor tissues were excised and sectioned after 3 days. Tissues were fixed in 10% buffered formalin and then rapidly paraffin-embedded. Apoptosis was detected by TUNEL assay. All procedures were performed according to protocols approved by the Institutional Animal Care and Use Committee of the Burnham Institute.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures, Supplemental References, and thirteen figures and can be found with this article online at http://www.cancercell.org/cgi/content/full/14/4/285/DC1/.
